TerminatedPHASE1, PHASE2NCT00052598
Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell Transplant
Studying Acute myeloid leukaemia with myelodysplasia-related features
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Fred Hutchinson Cancer Center
- Principal Investigator
- Gunnar RagnarssonFred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
- Intervention
- therapeutic allogeneic lymphocytes(biological)
- Enrollment
- 7 enrolled
- Eligibility
- All sexes
- Timeline
- 2002 – 2011
Study locations (1)
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00052598 on ClinicalTrials.govOther trials for Acute myeloid leukaemia with myelodysplasia-related features
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE2NCT04802161Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related ChangesNational Cancer Institute (NCI)
- RECRUITINGNCT01210274Characterization of the Mechanisms of Resistance to AzacitidineCentre Hospitalier Universitaire de Nice
See all trials for Acute myeloid leukaemia with myelodysplasia-related features →